Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024
10.11106/ijt.2024.17.1.115
- Author:
Mijin KIM
1
;
Ji-In BANG
;
Ho-Cheol KANG
;
Sun Wook KIM
;
Dong Gyu NA
;
Young Joo PARK
;
Youngduk SEO
;
Young Shin SONG
;
So Won OH
;
Sang-Woo LEE
;
Eun Kyung LEE
;
Ji Ye LEE
;
Dong-Jun LIM
;
Ari CHONG
;
Yun Jae CHUNG
;
Chae Moon HONG
;
Min Kyoung LEE
;
Bo Hyun KIM
;
Author Information
1. Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
- Publication Type:REVIEW ARTICLES
- From:International Journal of Thyroidology
2024;17(1):115-146
- CountryRepublic of Korea
- Language:English
-
Abstract:
Based on the clinical, histopathological, and perioperative data of a patient with differentiated thyroid cancer (DTC), risk stratification based on their initial recurrence risk is a crucial follow-up (FU) strategy during the first 1–2 years after initial therapy. However, restratifiying the recurrence risk on the basis of current clinical data that becomes available after considering the response to treatment (ongoing risk stratification, ORS) provides a more accurate prediction of the status at the final FU and a more tailored management approach. Since the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and DTC, the latest guidelines that include the National Comprehensive Cancer Network clinical practice and European Association for Medical Oncology guidelines have been updated to reflect several recent evidence in ORS and thyroid-stimulating hormone (TSH) suppression of DTC. The current clinical practice guideline was developed by extracting FU surveillance after the initial treatment section from the previous version of guidelines and updating it to reflect recent evidence. The current revised guideline includes recommendations for recent ORS, TSH target level based on risk stratification, FU tools for detection of recurrence and assessment of disease status, and long-term FU strategy for consideration of the disease status. These evidence-based recommendations are expected to avoid overtreatment and intensive FU of the majority of patients who will have a very good prognosis after the initial treatment of DTC patients, thereby ensuring that patients receive the most appropriate and effective treatment and FU options.
